A new perspective on the principles and functions of condensate modifying drugs (c-mods) was published in Frontiers in Molecular Biosciences.

BOSTON, Nov. 14, 2022 — Dewpoint Therapeutics Inc. today announced the U.S. Patent and Trademark Office (USPTO) issued the patent “Methods of Characterizing […]

BOSTON, September 22, 2022 – Dewpoint Therapeutics, Inc. today announced biomolecular scientist Anthony (Tony) Hyman, a co-founder of Dewpoint Therapeutics and Director […]

BOSTON, Massachusetts, August 17, 2022 – A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates […]

BOSTON, May 25, 2022 — Dewpoint Therapeutics Inc., today announced the US Patent and Trademark Office (USPTO) issued the patent “Methods of […]

BOSTON, February 28, 2022 — Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Aravind Subramanian, Ph.D., as Head of […]

BOSTON , February 3, 2022 – Dewpoint Therapeutics Inc., the biomolecular condensates company, today announced the completion of a $150 million Series C financing.

BOSTON, September 28, 2021— Dewpoint Therapeutics, the biomolecular condensates company, today announced the appointment of Lori Escobedo as Chief People Officer.